Streetbeat News

Regulatory

DISTW

Trading halt status was updated at 10:00:00 AM ET, with a quotation resumption. The news and resumption times were provided.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 2:00 pm

GILD

Gilead Sciences Inc (NASDAQ:GILD) announced positive interim results from the ASSURE study for seladelpar, a treatment for primary biliary cholangitis (PBC). The study showed improvements in disease markers and pruritus with no serious adverse events. A New Drug Application for seladelpar has been accepted for priority review by the FDA, with a decision expected in August 2024.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 1:36 pm

RGR

SWBI

The U.S. Supreme Court has rejected an appeal challenging Maryland's ban on assault weapons. This decision upholds the state's law, which prohibits the sale and possession of certain semi-automatic firearms. The ruling is significant for gun manufacturers and could impact companies like Sturm, Ruger & Company (RGR) and Smith & Wesson Brands, Inc. (SWBI).

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:33 pm

SPY

Fed's Barr highlights concerns about the discount window affecting banks of all sizes.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:31 pm

ATRA

Atara Biotherapeutics has submitted a Biologics License Application (BLA) to the FDA for tabelecleucel (tab-cel®) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Acceptance of the BLA will trigger a $20 million milestone payment from Pierre Fabre Laboratories, with an additional $60 million possible upon FDA approval.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:27 pm

SPY

Fed Vice Chair Barr stated that significant progress has been made in improving discount window operations, but more work remains. He hopes that a preparedness requirement will reduce the stigma and encourage usage of the discount window.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:24 pm

SPY

Fed Vice Chair Barr stated that the Federal Reserve aims to avoid a balance sheet size that could interfere with controlling the federal funds rate. He also mentioned that most funds in the private credit market are not from highly leveraged entities and face no run risk. However, if private credit markets were to move to an open-ended retail structure, it would be a cause for concern.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:20 pm

NKGN

NKGen Biotech Inc (NASDAQ:NKGN) shares surged 25.1% after the company's SNK01 NK Cell Therapy was cleared for a Phase 2 trial in Alzheimer's disease. The Phase 1 study showed promising safety and efficacy results, leading to FDA clearance for a new Phase 1/2a study with an increased dose.

Portfolio Pulse from Adam Eckert

May 20, 2024 | 1:17 pm

HSCS

HeartSciences (NASDAQ:HSCS) has been granted Indian Patent Application 201817014481 by the Indian Patent Office, adding to its portfolio of 44 granted patents, including nine in the US and 35 internationally.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:06 pm

HSDT

Helius Medical Technologies' PoNS device is now available on the VA Federal Supply Schedule and GSA Advantage contracts, providing U.S. veterans and government employees with access to this neurostimulation therapy for gait and balance impairment due to multiple sclerosis.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 1:02 pm